<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01764802</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-10077</org_study_id>
    <secondary_id>NCI-2012-01341</secondary_id>
    <secondary_id>1R21CA149675-01A1</secondary_id>
    <nct_id>NCT01764802</nct_id>
  </id_info>
  <brief_title>Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer</brief_title>
  <official_title>Psychosexual Intervention for Gynecologic and Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well psychosexual intervention works in patients
      with stage I-III gynecologic or breast cancer. Psychosexual intervention may improve sexual
      and psychosocial function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Efficacy for reducing the severity of sexual distress, difficulty, and dysfunction in a
      phase II randomized clinical trial (RCT).

      OUTLINE: Patients are randomized to 1 of 2 arms.

      ARM I (Enhanced standard care): Patients participate in enhanced standard care intervention
      comprising stress reduction, information delivery regarding gynecologic or breast cancer
      treatments and sexuality, and provision of a survivorship care plan (SCP) created using
      OncoLink over 1 hour following baseline assessment and before 6 months.

      ARM II (Psychological intervention): Patients participate in individual or group therapy over
      1.5 hours weekly for 4 weeks, bi-weekly for 8 weeks, and monthly for 2 months and complete
      assessment interviews.

      After completion of study treatment, patients are followed up at 3, 6, and 9 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2010</start_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sexual behavior/repertoire (kissing, intercourse, etc.) graded using the Sexual Experiences Scale (SES)</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>Multilevel modeling will be used to model time effects compared to repeated-measures analysis of variance (ANOVA) because it allows not only fitting different patterns of average change (i.e., linear, quadratic), but also estimates individual variability in the rate of change. Both linear and quadratic change models will be tested and an optimal model will be determined. 95% confidence intervals will be obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sexual responsiveness (desire, arousal, orgasm) using the Female Sexual Functioning Index (FSFI)</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Principal components analysis yields six subscales: desire, arousal, lubrication, orgasm, satisfaction, and pain. Items are rated using the Likert scales. 95% confidence intervals will be obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sexual satisfaction graded using the global evaluation from the Derogatis Sexual Function Inventory (DSFI)</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>95% confidence intervals will be obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sexual distress graded using the female Sexual Distress Scale (FSDS)</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>The Likert scale will be used. 95% confidence intervals will be obtained.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sexual pain graded using the International Pelvic Pain Society Pelvic Pain Assessment, patient/physician version</measure>
    <time_frame>Up to 9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Emotional distress graded using the Profile of Mood States (POMS)</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>The Likert scale will be used. 95% confidence intervals will be obtained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depressive symptoms graded using the Center for Epidemiologic Studies Depression Scale (CES-D)</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>The Likert scale will be used. 95% confidence intervals will be obtained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life graded according to the RAND Medical Outcomes Study, Short-form 12 (SF-12)</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>The eight primary subscales are summarized into two component scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer-related stress graded according to the Impact of Events Scale-Revised (IES-R)</measure>
    <time_frame>Up to 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body change stress graded according to the Impact of Treatment Scale (ITS)</measure>
    <time_frame>Up to 9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ovarian Sarcoma</condition>
  <condition>Ovarian Stromal Cancer</condition>
  <condition>Stage I Uterine Sarcoma</condition>
  <condition>Stage I Vaginal Cancer</condition>
  <condition>Stage I Vulvar Cancer</condition>
  <condition>Stage IA Cervical Cancer</condition>
  <condition>Stage IA Endometrial Carcinoma</condition>
  <condition>Stage IA Fallopian Tube Cancer</condition>
  <condition>Stage IA Ovarian Epithelial Cancer</condition>
  <condition>Stage IA Ovarian Germ Cell Tumor</condition>
  <condition>Stage IA Primary Peritoneal Cavity Cancer</condition>
  <condition>Stage IB Cervical Cancer</condition>
  <condition>Stage IB Endometrial Carcinoma</condition>
  <condition>Stage IB Fallopian Tube Cancer</condition>
  <condition>Stage IB Ovarian Epithelial Cancer</condition>
  <condition>Stage IB Ovarian Germ Cell Tumor</condition>
  <condition>Stage IB Primary Peritoneal Cavity Cancer</condition>
  <condition>Stage IC Fallopian Tube Cancer</condition>
  <condition>Stage IC Ovarian Epithelial Cancer</condition>
  <condition>Stage IC Ovarian Germ Cell Tumor</condition>
  <condition>Stage IC Primary Peritoneal Cavity Cancer</condition>
  <condition>Stage II Endometrial Carcinoma</condition>
  <condition>Stage II Gestational Trophoblastic Tumor</condition>
  <condition>Stage II Uterine Sarcoma</condition>
  <condition>Stage II Vaginal Cancer</condition>
  <condition>Stage II Vulvar Cancer</condition>
  <condition>Stage IIA Cervical Cancer</condition>
  <condition>Stage IIA Fallopian Tube Cancer</condition>
  <condition>Stage IIA Ovarian Epithelial Cancer</condition>
  <condition>Stage IIA Ovarian Germ Cell Tumor</condition>
  <condition>Stage IIA Primary Peritoneal Cavity Cancer</condition>
  <condition>Stage IIB Cervical Cancer</condition>
  <condition>Stage IIB Fallopian Tube Cancer</condition>
  <condition>Stage IIB Ovarian Epithelial Cancer</condition>
  <condition>Stage IIB Ovarian Germ Cell Tumor</condition>
  <condition>Stage IIB Primary Peritoneal Cavity Cancer</condition>
  <condition>Stage IIC Fallopian Tube Cancer</condition>
  <condition>Stage IIC Ovarian Epithelial Cancer</condition>
  <condition>Stage IIC Ovarian Germ Cell Tumor</condition>
  <condition>Stage IIC Primary Peritoneal Cavity Cancer</condition>
  <condition>Stage III Gestational Trophoblastic Tumor</condition>
  <condition>Stage III Uterine Sarcoma</condition>
  <condition>Stage III Vaginal Cancer</condition>
  <condition>Stage III Vulvar Cancer</condition>
  <condition>Stage IIIA Cervical Cancer</condition>
  <condition>Stage IIIA Endometrial Carcinoma</condition>
  <condition>Stage IIIA Fallopian Tube Cancer</condition>
  <condition>Stage IIIA Ovarian Epithelial Cancer</condition>
  <condition>Stage IIIA Ovarian Germ Cell Tumor</condition>
  <condition>Stage IIIA Primary Peritoneal Cavity Cancer</condition>
  <condition>Stage IIIB Cervical Cancer</condition>
  <condition>Stage IIIB Endometrial Carcinoma</condition>
  <condition>Stage IIIB Fallopian Tube Cancer</condition>
  <condition>Stage IIIB Ovarian Epithelial Cancer</condition>
  <condition>Stage IIIB Ovarian Germ Cell Tumor</condition>
  <condition>Stage IIIB Primary Peritoneal Cavity Cancer</condition>
  <condition>Stage IIIC Endometrial Carcinoma</condition>
  <condition>Stage IIIC Fallopian Tube Cancer</condition>
  <condition>Stage IIIC Ovarian Epithelial Cancer</condition>
  <condition>Stage IIIC Ovarian Germ Cell Tumor</condition>
  <condition>Stage IIIC Primary Peritoneal Cavity Cancer</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (enhanced standard care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients participate in enhanced standard care intervention comprising stress reduction, information delivery regarding cancer treatments and sexuality delivered over two sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (psychological intervention)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients participate in individual or group therapy over 1.5 hours weekly for 6 weeks, bi-weekly for 8 weeks, and monthly for 2 months and complete assessment interviews.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>behavioral, psychological or informational intervention</intervention_name>
    <description>Participate in enhanced standard care</description>
    <arm_group_label>Arm I (enhanced standard care)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>behavioral, psychological or informational intervention</intervention_name>
    <description>Participate in psychological intervention</description>
    <arm_group_label>Arm II (psychological intervention)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage I-III gynecologic (any site) or breast cancer

          -  Able to speak/read English

          -  Able to give informed consent

        Exclusion Criteria:

          -  Prior non-gynecologic/breast cancer diagnosis

          -  Refusal of any cancer treatment(s)

          -  Non-ambulatory

          -  Concurrent diagnosis of organic brain syndrome, dementia, mental retardation, or
             significant sensory deficit

          -  Major mental illness (e.g, schizophrenia, major depressive disorder)

          -  Current/recent (prior 12 months) pregnancy

          -  Residence &gt; 70 miles from research site
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristen M. Carpenter, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ohio State University Comprehensive Cancer Center</last_name>
    <phone>1-800-293-5066</phone>
    <email>Jamesline@osumc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nichole Storey</last_name>
    <phone>614-685-8754</phone>
    <email>nichole.storey@osumc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nichole Storey</last_name>
      <phone>614-685-8754</phone>
      <email>nichole.storey@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Carpenter Kristen, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andersen Barbara, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fowler Jeffrey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Salani Ritu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lustberg Maryum, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>Jamesline</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2013</study_first_submitted>
  <study_first_submitted_qc>January 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2013</study_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Kristen Carpenter</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Psychosexual Intervention</keyword>
  <keyword>Cancer</keyword>
  <keyword>Gynecologic Cancer</keyword>
  <keyword>Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Germinoma</mesh_term>
    <mesh_term>Vulvar Neoplasms</mesh_term>
    <mesh_term>Vaginal Neoplasms</mesh_term>
    <mesh_term>Trophoblastic Neoplasms</mesh_term>
    <mesh_term>Gestational Trophoblastic Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

